The estimated Net Worth of Charles Evan Ballantyne is at least $10.2 Thousand dollars as of 25 September 2015. Charles Ballantyne owns over 10,000 units of Theriva Biologics Inc stock worth over $10,200 and over the last 11 years Charles sold SYN stock worth over $0.
Charles has made over 2 trades of the Theriva Biologics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Charles bought 10,000 units of SYN stock worth $50,500 on 25 September 2015.
The largest trade Charles's ever made was buying 10,000 units of Theriva Biologics Inc stock on 25 September 2015 worth over $50,500. On average, Charles trades about 2,500 units every 61 days since 2014. As of 25 September 2015 Charles still owns at least 10,000 units of Theriva Biologics Inc stock.
You can see the complete history of Charles Ballantyne stock trades at the bottom of the page.
Charles's mailing address filed with the SEC is C/O SYNTHETIC BIOLOGICS, INC.,, 155 GIBBS STREET, SUITE 412, ROCKVILLE, MD, 20850.
Over the last 13 years, insiders at Theriva Biologics Inc have traded over $8,016,723 worth of Theriva Biologics Inc stock and bought 6,682,900 units worth $10,572,593 . The most active insiders traders include Randal Jintrexon Corp Kirk, Steve H Kanzer, and Scott Tarriff. On average, Theriva Biologics Inc executives and independent directors trade stock every 223 days with the average trade being worth of $899,000. The most recent stock trade was executed by Steven A Shallcross on 10 May 2021, trading 50,000 units of SYN stock currently worth $24,500.
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Theriva Biologics Inc executives and other stock owners filed with the SEC include: